The stock markets are moving forward from the US job report. Hyloris adds a heart agent to his pipeline. Half moon in charging stations. Bpost writes letters.
With the US Senate agreeing to a temporary increase in the debt ceiling, a headache is already gone. The agreement sparked optimism in New York and Asia, but leaves Europe cold. Around 50 o’clock the Euroxx 50 is 0.2 percent lower, but on a weekly basis the 12 index is still on the gain of Thursday’s rally (+2.1%). This was due to energy prices, in which Russian President Putin played a key role.
The downward trend has to do with caution. At 2:30 p.m. US jobs report is published. If that’s “proper” — it won’t even be super — the Federal Reserve could kick off in November to begin phasing out the emergency stimulus.
The Bel20 . rings in Brussels
0.1 percent higher to 4,155 points. The mainstays in the index are stainless steel producer Aperam
(+1.1%), materials technology group Umicore
(+1.4%) and Telenet
Pressure comes from, among other things Ageas
, which leaves 1.4 percent to 41.41 euros. Kepler Cheuvreux puts the scissors in his price target for the insurance group. The brokerage has adjusted estimates for Ageas’s results in 2022 with a 2 percent reduction in Taiping Life insurance premiums in the sum-of-its-parts valuation. The analyst does not expect any major surprises for the third quarter results that Ageas will announce on 10 November. He processes his price target of 48.70 to 42.30 euros and calculates his ‘decrease’ advice.
Two out of four
has completed its pipeline with an innovative cardiovascular product, CRD-102. It involves an oral long-acting of Milrinone intended to have developed, treat patients with heart failure. Milrinone strengthens the heart’s contractions so that it can pump more blood with fewer beats.
Hyloris has acquired the rights to CRD-102 from the Baker Heart and Diabetes Institute in Melbourne. The Liège, which is in charge of further development, production and commercialization, the originally born $50,000. The Baker Institute is also entitled to sales-related milestone payments and a share of the profits on the subsequent sale.
CRD-103 has successfully completed Phase 1 and 2 clinical studies. Hyloris hopes to launch the landmark Phase 3 trial by late 2022 or early 2023.
KBC Securities’ biotech analysts estimate the net value of the project at 15 to 20 million euros. They increase their price target by half a euro from 15 to 15.50 euros. Their valuation remains at ‘buy’.
Lenny Van Steenhuyse and Thomas point out that Hyloris had the prospect of adding four pipeline candidates for this year. Two of them are already in. They believe that CRD-102 could eventually hit the market in 2025/26. According to them, Hyloris is counting on peak sales between 50 and 80 million dollars.
Hyloris wins 3.8 percent to 13.55 euros.
Short shipping will be more expensive next year. Especially for prior stamps increase in price. bpost
says the price increase is necessary to do the cost per letter provided.
Thomas Couvreur of KBC Securities that the average percentage of mail items will be 4.7 more expensive. That will partly input the normalization of the decline in mail volume in 2022, he says. His price target (11 euros) and advice (buy) will not change.
The Bpost share rose 0.8 percent to 7.75 euros.
, formerly Option, establishes E+ Drive together with ‘a few strong partners’ and thus also becomes active in charging stations. E+ Drive will offer public authorities and private companies a complete charging station, from excavation work and permits, installation and electrical installation to maintenance, insurance and financing.
According to Crescent, the charging stations are ‘top quality’ and are produced by Powerdale and Phoenix Contact, among others. The companies APK and Jacops take care of installation and maintenance, while the bodies of Option and Remoticom, which may or may not be set up, come.
“This initiative aligns with Crescent’s announced strategy to bring end-to-end published IOT (Internet of Things) solutions into the market to start with more advanced sensor technology and software,” said a press release.
The penny share Crescent climbs 4.2 percent to 0.03 euros.